Literature DB >> 33801921

Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions.

Yujiro Matsuishi1,2,3, Bryan J Mathis4, Nobutake Shimojo1, Jesmin Subrina3, Nobuko Okubo5, Yoshiaki Inoue1.   

Abstract

Since December 2019, the SARS-CoV-2 (COVID-19) pandemic has transfixed the medical world. COVID-19 symptoms vary from mild to severe and underlying chronic conditions such as pulmonary/cardiovascular disease and diabetes induce excessive inflammatory responses to COVID-19 and these underlying chronic diseases are mediated by endothelial dysfunction. Acute respiratory distress syndrome (ARDS) is the most common cause of death in COVID-19 patients, but coagulation induced by excessive inflammation, thrombosis, and disseminated intravascular coagulation (DIC) also induce death by multiple-organ dysfunction syndrome. These associations imply that maintaining endothelial integrity is crucial for favorable prognoses with COVID-19 and therapeutic intervention to support this may be beneficial. Here, we summarize the extent of heart injuries, ischemic stroke and hemorrhage, acute kidney injury, and liver injury caused by immune-mediated endothelial dysfunction that result in the phenomenon of multi-organ dysfunction seen in COVID-19 patients. Moreover, the potential therapeutic effect of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors that improve endothelial dysfunction as well as the bradykinin storm are discussed.

Entities:  

Keywords:  ACE-I; ACE2; ARBs; COVID-19; bradykinin; endothelial dysfunction

Year:  2021        PMID: 33801921      PMCID: PMC7999560          DOI: 10.3390/biomedicines9030279

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  140 in total

1.  von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation.

Authors:  Martine J Hollestelle; Cynthia Donkor; Ebenezer Akrofi Mantey; Srabasti J Chakravorty; Alister Craig; Alex Osei Akoto; James O'Donnell; Jan A van Mourik; James Bunn
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

2.  Vitamin D3 to Treat COVID-19: Different Disease, Same Answer.

Authors:  David E Leaf; Adit A Ginde
Journal:  JAMA       Date:  2021-03-16       Impact factor: 56.272

3.  Circulating endothelin-1 concentrations in acute respiratory failure.

Authors:  C Mitaka; Y Hirata; T Nagura; Y Tsunoda; K Amaha
Journal:  Chest       Date:  1993-08       Impact factor: 9.410

4.  Clinical and immunological features of severe and moderate coronavirus disease 2019.

Authors:  Guang Chen; Di Wu; Wei Guo; Yong Cao; Da Huang; Hongwu Wang; Tao Wang; Xiaoyun Zhang; Huilong Chen; Haijing Yu; Xiaoping Zhang; Minxia Zhang; Shiji Wu; Jianxin Song; Tao Chen; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

5.  Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.

Authors:  Wei Tang; Zhujun Cao; Mingfeng Han; Zhengyan Wang; Junwen Chen; Wenjin Sun; Yaojie Wu; Wei Xiao; Shengyong Liu; Erzhen Chen; Wei Chen; Xiongbiao Wang; Jiuyong Yang; Jun Lin; Qingxia Zhao; Youqin Yan; Zhibin Xie; Dan Li; Yaofeng Yang; Leshan Liu; Jieming Qu; Guang Ning; Guochao Shi; Qing Xie
Journal:  BMJ       Date:  2020-05-14

6.  The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure.

Authors:  Philip Keith; Matthew Day; Carol Choe; Linda Perkins; Lou Moyer; Erin Hays; Marshall French; Kristi Hewitt; Gretchen Gravel; Amanda Guffey; L Keith Scott
Journal:  SAGE Open Med Case Rep       Date:  2020-06-18

7.  NeuroCOVID: it's time to join forces globally.

Authors:  Raimund Helbok; Sherry Hsiang-Yi Chou; Ettore Beghi; Shraddha Mainali; Jennifer Frontera; Courtney Robertson; Ericka Fink; Michelle Schober; Elena Moro; Molly McNett; Claudio L Bassetti
Journal:  Lancet Neurol       Date:  2020-09-16       Impact factor: 44.182

8.  SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection.

Authors:  Rafal Butowt; Katarzyna Bilinska
Journal:  ACS Chem Neurosci       Date:  2020-04-13       Impact factor: 4.418

Review 9.  Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.

Authors:  Juan Simon Rico-Mesa; Averi White; Allen S Anderson
Journal:  Curr Cardiol Rep       Date:  2020-04-14       Impact factor: 2.931

10.  The ADAMTS13-von Willebrand factor axis in COVID-19 patients.

Authors:  Ilaria Mancini; Luciano Baronciani; Andrea Artoni; Paola Colpani; Marina Biganzoli; Giovanna Cozzi; Cristina Novembrino; Massimo Boscolo Anzoletti; Valentina De Zan; Maria Teresa Pagliari; Roberta Gualtierotti; Stefano Aliberti; Mauro Panigada; Giacomo Grasselli; Francesco Blasi; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-12-18       Impact factor: 16.036

View more
  11 in total

1.  Mechanism of Multi-Organ Injury in Experimental COVID-19 and Its Inhibition by a Small Molecule Peptide.

Authors:  Michael J Paidas; Natarajan Sampath; Emma A Schindler; Daniela S Cosio; Chima Obianuju Ndubizu; Nagarajarao Shamaladevi; Jaclyn Kwal; Suset Rodriguez; Anis Ahmad; Norma Sue Kenyon; Arumugam R Jayakumar
Journal:  Front Pharmacol       Date:  2022-05-30       Impact factor: 5.988

Review 2.  Thromboembolic Complications in Covid-19: From Clinical Scenario to Laboratory Evidence.

Authors:  Alberto Palazzuoli; Michela Giustozzi; Gaetano Ruocco; Francesco Tramonte; Edoardo Gronda; Giancarlo Agnelli
Journal:  Life (Basel)       Date:  2021-04-27

3.  Single-Cell and Bulk RNASeq Profiling of COVID-19 Patients Reveal Immune and Inflammatory Mechanisms of Infection-Induced Organ Damage.

Authors:  Alexandrea Bass; Yiran Liu; Sivanesan Dakshanamurthy
Journal:  Viruses       Date:  2021-12-02       Impact factor: 5.048

4.  Cardiopulmonary Exercise Performance and Endothelial Function in Convalescent COVID-19 Patients.

Authors:  Pasquale Ambrosino; Paolo Parrella; Roberto Formisano; Giovanni Perrotta; Silvestro Ennio D'Anna; Marco Mosella; Antimo Papa; Mauro Maniscalco
Journal:  J Clin Med       Date:  2022-03-07       Impact factor: 4.241

5.  A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19.

Authors:  Serafino Fazio; Flora Affuso; Paolo Bellavite
Journal:  Med Sci Monit       Date:  2022-03-08

6.  Angiotensin II Exaggerates SARS-CoV-2 Specific T-Cell Response in Convalescent Individuals following COVID-19.

Authors:  Moudhi Almutlaq; Fatmah A Mansour; Jahad Alghamdi; Yassen Alhendi; Abir Abdullah Alamro; Amani Ahmed Alghamdi; Hassan S Alamri; Fayhan Alroqi; Tlili Barhoumi
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

7.  Simulation of COVID-19 symptoms in a genetically engineered mouse model: implications for the long haulers.

Authors:  Mahavir Singh; Sathnur Pushpakumar; Nia Bard; Yuting Zheng; Rubens P Homme; Sri Prakash L Mokshagundam; Suresh C Tyagi
Journal:  Mol Cell Biochem       Date:  2022-06-22       Impact factor: 3.842

Review 8.  Noninvasive respiratory support and patient self-inflicted lung injury in COVID-19: a narrative review.

Authors:  Denise Battaglini; Chiara Robba; Lorenzo Ball; Pedro L Silva; Fernanda F Cruz; Paolo Pelosi; Patricia R M Rocco
Journal:  Br J Anaesth       Date:  2021-06-03       Impact factor: 11.719

9.  Clinical Assessment of Endothelial Function in Convalescent COVID-19 Patients Undergoing Multidisciplinary Pulmonary Rehabilitation.

Authors:  Pasquale Ambrosino; Antonio Molino; Ilenia Calcaterra; Roberto Formisano; Silvia Stufano; Giorgio Alfredo Spedicato; Andrea Motta; Antimo Papa; Matteo Nicola Dario Di Minno; Mauro Maniscalco
Journal:  Biomedicines       Date:  2021-05-28

Review 10.  Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic Manifestations.

Authors:  Jonathan D Ravid; Orly Leiva; Vipul C Chitalia
Journal:  Cells       Date:  2022-01-17       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.